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Abstract. Morphological abnormalities observed typically in the brains of adults with Down syndrome are identical with
those present in patients with Alzheimer’s disease. However, only some adults with Down syndrome suffer from early dementia,
whereas others remain unaffected. We aimed to identify the genomic background responsible for this observation. We performed
cognitive assessment and genome expression analysis of blood mononuclear cells in seniors with Down syndrome. Unaffected
elderly patients and younger patients with severe cognitive disability or cognitive deterioration differed significantly with regard
to the MTRNR2L12 gene. Our findings suggest the potential value of this gene as a blood marker of early dementia in individuals
with Down syndrome.
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INTRODUCTION
Histological changes typical of Alzheimer’s disease
(AD) are constantly reported in autopsied brain tissue
of deceased individuals with Down syndrome (trisomy
21) older than 30–40 years [1–3]. This fact suggests
the important role that the overexpression of genes
encoded on the 21st chromosome plays in the devel-
opment of AD. In particular, the APP gene encoding
amyloid- protein precursor is an obvious candidate
due to its role in the development of amyloid plaques.
Nevertheless, genome-wide association studies sug-
gest the importance of several other genes [4].
Interestingly, significant variability of cognitive pro-
files can be observed in adult persons with Down
syndrome. On the one hand, symptoms of AD-like
dementia develop in these individuals frequently in
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the fourth or fifth decade of life. On the other hand,
some seniors with Down syndrome remain unaffected
by AD-like dementia. This phenomenon suggests the
presence of genetic variability that influences meta-
bolic pathways crucial for the development of AD-like
dementia in individuals with Down syndrome.
Although genome expression is tissue specific, it has
been suggested that several genes play central roles
in ubiquitous metabolic pathways following similar
expression patterns in the brain and the blood [5, 6].
Consequently, the alteration of genome expression in
the brain in the case of AD development might be
partially detectable in the blood.
In light of these facts, we aimed to find potential
genomic blood markers of AD-like dementia develop-
ment in adults with Down syndrome.
METHODS
We focused on a cohort of 48 adults with Down syn-
drome older than 35 years who were institutionalized
or attended day-care centers; these individuals were
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recruited from the five largest cities in Poland. All
of these persons or their legal representatives signed
informed consent forms to participate in the study and
the protocol was accepted by the Jagiellonian Univer-
sity Ethics Committee.
To enable the detection of potential markers of early
dementia, the participants were divided into two age
groups: younger persons (younger than 55) and older
persons (older than 55). The cognitive function of each
study participant was assessed using the short form
of the Prudhoe Cognitive Function Test (PCFT) [7].
Cognitive status was defined as good/acceptable for
PCFT scores above 25%; a severe cognitive disability
was inferred from PCFT scores below 25%. Further-
more, disability was presumed if administration of the
PCFT was not possible due to the person’s inability
to cooperate. History of cognitive deterioration within
last three years was also recorded in persons younger
than 55 if reported by a caregiver or appropriate med-
ical records. In all assessed persons, hypothyroidism
was excluded as well as poorly controlled epilepsy and
other serious medical conditions, which could result in
cognitive decline.
We next conducted the genomic study. Subgroups
of patients with good/acceptable cognitive statuses
and individuals with severe cognitive disabilities from
both age categories were cross compared. In addi-
tion, subgroups of younger persons with a history
of cognitive deterioration and older participants with
good/acceptable cognitive statuses were compared.
Blood samples (2.5 mL) were obtained from the
study participants and used to extract total RNA from
blood white cells (PAXgene system; PreAnalytiX).
The whole genome expression was next assessed
using SurePrint Human Gene Expression 8 × 60K v2
Microarrays (Agilent, Santa Clara, USA) that were
scanned on an Agilent SureScan G2600D scanner
according to the manufacturer’s protocol. SurePrint
G3 Human Gene Expression Microarrays provide a
comprehensive coverage of the entire human genome
(50.599 genes and transcripts) with a high speci-
ficity of target detection and a very wide dynamic
range. This analysis allows for detection of biological
features encompassing both very high and very low
expression.
We performed microarray data analysis using Gene-
Spring Software (http://www.genespring.com). We
also used single-color expression technology dedicated
to Agilent microarrays. For detecting statistically sig-
nificant differences between the subgroups of study
participants, we used a moderated t-test. We also
applied a Benjamini-Hochberg false discovery rate
(FDR) correction for multiple testing. A corrected
value of p < 0.05 was considered significant with fold
change (FC) greater than 2.
The primary microarray data were added to the
GEO public repository and are accessible via GEO
Series accession number GSE63870 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63870).
The validation of the microarray data was performed
using Real-Time Quantitative PCR (RQ-PCR). A total
of 120 ng of RNA was used for the reverse transcription
of each sample by means of Superscript II reverse tran-
scriptase (Life Technologies, Carlsbad, USA). Next,
SYBR Green chemistry was employed for measuring
the gene expression (measurements in duplication),
with the beta-2-microglobulin gene (B2M) serving
as the control gene (the sequences of the starters
are 5’- GAGTATGCCTGCCGTGTG-3’ and 5’-
AATCCAAATGCGGCATCT-3’). ABI PRISM 7300
Real-time PCR System (Life Technologies, Carlsbad,
USA) with a universal instrument setting was used.
We performed the data analysis using the comparative
cycle threshold (Ct) method of relative quantifi-
cation (Ct = Ct(gene of interest)-Ct(control gene); Ct =
Ct(tested group)-Ct(control group); FC = 2−Ct).
RESULTS
A group of 23 women (aged 35–67 years; mean age:
49 years) and 25 men (aged 35–67 years; mean age:
46 years) entered the study. Among them, 36 persons
(aged 37–67 years; mean age: 50 years) were insti-
tutionalized and 12 persons (aged 35–57 years; mean
age: 40 years) lived with their families and attended
day-care centers. The “younger” and the “older” sub-
groups of the study participants consisted of 35 persons
and 13 persons, respectively. Severe cognitive dis-
ability was not recorded in patients younger than 40.
Good/acceptable cognitive function and severe cogni-
tive disability were observed in 33 and 15 participants,
respectively. The frequency of severe disability was
similar for women (8/23) and for men (7/25). Only one
severely disabled person attended a day-care center.
The PCFT scores in the subgroups of persons
with good/acceptable cognitive function ranged from
15/30–30/30 points (mean: 26/30) in the younger sub-
group and 17/30–29/30 points (mean: 20/30) in the
older subgroup. In the group with severe cognitive dis-
ability, the PCFT could be administered only in three
cases (the scores ranged from 4/30–6/30 points).
Cognitive deterioration was recorded in five per-
sons younger than 55. In two cases with documented
deterioration, administration of the PCFT was possi-
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Table 1
The participants of the study
Patient’s Age Gender Day-care center/ Age group Cognitive status Cognitive PCFT score
Code Institutionalized deterioration (Short form of the test,
<55 y maximal score = 30 points)
1 53 M Institutionalized Younger Severe disability Yes Inability to cooperate
2 50 F Institutionalized Younger Severe disability Inability to cooperate
3 48 M Institutionalized Younger Severe disability 6/30
4 47 F Institutionalized Younger Severe disability Yes Inability to cooperate
5 45 M Institutionalized Younger Severe disability Inability to cooperate
6 40 M Day-care center Younger Severe disability 6/30
7 40 F Institutionalized Younger Severe disability Yes Inability to cooperate
8 62 M Institutionalized Older Good/acceptable 17/30
9 62 M Institutionalized Older Good/acceptable 14/16∗
10 60 F Institutionalized Older Good/acceptable 25/30
11 59 F Institutionalized Older Good/acceptable 29/30
12 57 F Day-care center Older Good/acceptable 25/30
13 52 F Institutionalized Younger Good/acceptable Yes 15/30
14 50 M Institutionalized Younger Good/acceptable Yes 23/30
15 47 F Institutionalized Younger Good/acceptable 30/30
16 47 M Institutionalized Younger Good/acceptable 24/30
17 47 F Institutionalized Younger Good/acceptable 20/30
18 45 F Day-care center Younger Good/acceptable 19/30
19 45 F Institutionalized Younger Good/acceptable 18/30
20 44 M Institutionalized Younger Good/acceptable 28/30
21 44 M Institutionalized Younger Good/acceptable 22/30
22 44 M Institutionalized Younger Good/acceptable 16/30
23 43 F Institutionalized Younger Good/acceptable 27/30
24 43 M Institutionalized Younger Good/acceptable 20/30
25 42 M Day-care center Younger Good/acceptable 30/30
26 40 F Day-care center Younger Good/acceptable 30/30
27 40 M Institutionalized Younger Good/acceptable 29/30
28 40 M Day-care center Younger Good/acceptable 24/30
29 40 M Institutionalized Younger Good/acceptable 20/30
30 39 F Institutionalized Younger Good/acceptable 30/30
31 39 M Institutionalized Younger Good/acceptable 27/30
32 38 F Day-care center Younger Good/acceptable 30/30
33 38 F Institutionalized Younger Good/acceptable 28/30
34 38 M Day-care center Younger Good/acceptable 21/30
35 37 M Institutionalized Younger Good/acceptable 29/30
36 37 M Institutionalized Younger Good/acceptable 28/30
37 36 M Day-care center Younger Good/acceptable 30/30
38 36 M Day-care center Younger Good/acceptable 30/30
39 36 F Day-care center Younger Good/acceptable 16/30
40 35 F Day-care center Younger Good/acceptable 28/30
41 67 F Institutionalized Older Severe disability ∗∗ Inability to cooperate
42 67 M Institutionalized Older Severe disability ∗∗ Inability to cooperate
43 64 F Institutionalized Older Severe disability 4/30
44 63 M Institutionalized Older Severe disability ∗∗ Inability to cooperate
45 63 F Institutionalized Older Severe disability ∗∗ Inability to cooperate
46 62 F Institutionalized Older Severe disability ∗∗ Inability to cooperate
47 60 M Institutionalized Older Severe disability Inability to cooperate
48 58 F Institutionalized Older Severe disability Inability to cooperate
∗Only partial application of the test possible because of serious visual impairment in the patient (questions requiring visual skills were omitted).
∗∗Various degree of cognitive decline observed in the last years.
ble (these participants scored 15/30 and 23/30 points,
respectively).
Details of the studied population are summarized in
Table 1.
An initial comparison of the younger and older sub-
groups by means of microarrays revealed significant
differences with regard to three transcripts (ESPNL,
XLOC 007536 and USP27X-AS1). However, these
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Fig. 1. Expression of the MTRNR2L12 gene. Comparison of the groups of older (>55 y) patients with good/acceptable cognitive status and
of younger (<55 y) patients with severe cognitive disability is presented on the left. Comparison of the same group of older patients with the
group of younger (<55 y) patients with documented dementia is depicted on the right. Normalized intensity values representing expression of
the MTRNR2L12 gene (microarray analysis) are visible above whereas the corresponding -Ct values (the RQ-PCR confirmatory analysis) are
shown below.
transcripts do not seem to be involved in the
pathogenesis of dementia. No significant differences
were detected when comparing the group with
good/acceptable cognitive statuses and the group with
severe cognitive disabilities. On the other hand, sub-
groups of younger patients with severe cognitive
disabilities (n = 7) and patients with cognitive deteri-
oration (n = 5) differed significantly when compared
with older patients with good/acceptable cognitive
statuses (n = 5; corrected p = 0.00026 and 0.00024;
FC = 17.76 and 18.66, respectively) with regard to the
expression of a single gene: MTRNR2L12, an isoform
of humanin, considered to be a protective factor in
familial AD [8].
Since no commercial RQ-PCR assays for expres-
sion measurement of the MTRNR2L12 gene are
available on the market, specific starters were
designed, based on the sequence of the tran-
script ENST00000600213 (http://www.ensembl.org)
and the sequence of the respective microarray
probe (A 21 P0003289) located on the SurePrint
Human Gene Expression 8×60K v2 Microarray.
Starters with the following sequences were used:
5’- GCTGTCTCTTACTTTCAACCAGTG-3’ (for-
ward) and 5’- CATAGTCTTGCTATGTTATGCCCG-
3’ (reverse). A validation procedure with SYBR
Green chemistry confirmed the expression difference
discussed above for younger patients with severe
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Table 2
Details of the statistical analysis
Compared subgroups of patients Number of Number of Names of the RQ-PCR
upregulated statistically statistically significant validation
genes/downregulated significant genes
genes (FC >2, genes
uncorrected p) (corrected p)
Older (>55 y) versus younger 379 / 316 3 ESPNL Not analyzed
(<55 y) (FC = 2.2; p = 0.047)
XLOC 007536
(FC = 2.08; p = 0.047)
USP27X-AS1
(FC = 2.03; p = 0.047)
Good/acceptable cognitive status 31 / 59 0 – Not analyzed
versus severe cognitive disability
Institutionalized versus day-care 34 / 82 0 – Not analyzed
center
Older (>55 y) with 1376 / 794 1 MTRNR2L12 Ct = −5.36
good/acceptable cognitive status (FC = 17.76; FC = 41,
versus younger (<55 y) with p = 0.00026) p < 0.0001
severe intellectual disability
Older (>55 y) with 971 / 1301 1 MTRNR2L12 Ct = −5.16
good/acceptable cognitive status (FC = 18.66; FC = 35.7
versus younger (<55 y) with p = 0.00024) p < 0.0001
cognitive deterioration
cognitive disabilities and individuals with cogni-
tive deterioration, compared with older patients with
good/acceptable cognitive statuses (Ct = −5.36;
FC = 41; p < 0.0001 and Ct = −5.16; FC = 35.7;
p < 0.0001, respectively).
The results of the genomic study are shown in Fig. 1
and in Table 2.
DISCUSSION
The PCFT is easy to administer, which was val-
idated for the detection of cognitive decline and
oncoming dementia. The degree of intellectual dis-
ability strongly correlates with PCFT score. However,
it should be noted that potential dynamics of the
symptoms of cognitive disability were not assessed
in the present study, since each participant was
examined only once. Therefore, a conclusive differen-
tiation between rapid cognitive deterioration (typical
of early-onset AD) and baseline severe intellectual
disability related to Down syndrome itself was pos-
sible only in a few patients based on symptoms
reported by the caregivers or medical records, if avail-
able. Nevertheless, the genomic analysis revealed very
similar results for younger patients with severe cog-
nitive disability and younger patients with cognitive
deterioration.
Although the findings of the present study are lim-
ited by the relatively small sample size, the results
of the genome expression analysis suggest a possi-
ble role of MTRNR2L12, a humanin isoform, in the
early development of dementia in Down syndrome.
Humanin is a polypeptide that is highly conserved
across species [8, 9]. It is a 24 amino acid-long
molecule encoded by a 75bp open reading frame
sequence of the mitochondrial 16S rRNA (MT-RNR2
gene). Humanin was shown to restore cellular ATP lev-
els and to protect against several AD-related toxicities
in neuronal cells by means of modulation of oxidative
stress and apoptosis [8]. It is secreted from cells and
can be found in plasma.
Bioinformatic studies revealed several MT-RNR2-
like nuclear loci encoding 15 humanin-like peptides
[10]. The MTRNR2L12 gene located on chromosome
3 (3q11.2) is nearly identical to the mitochondrial gene
MT-RNR2 encoding humanin. Interestingly, there is
a polymorphic site (rs6484338) within MTRNR2L12,
predicted to cause the Ser12Leu amino acid exchange,
which in turn results in the production of a peptide
sequence identical to mitochondrial humanin. Since
the presence of the MTRNR2L12 peptide has been
confirmed in brain tissue, it can be assumed that
MTRNR2L12 exerts effects similar to those reported
for humanin.
In conclusion, the expression of MTRNR2L12
might be a new, easy-to-measure blood marker
of severe cognitive disability and, possibly, of
early dementia in patients with Down syndrome.
Further studies should be performed in order
to evaluate the potential usefulness of the mea-
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surement of MTRNR2L12 transcript in patients
with AD.
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